Solutions For Patients

Many therapies for treating cancer and infectious disease severely weaken the immune system - the human body's most important natural disease-fighting weapon. But ImmunityBio creates targeted, personalized immunotherapies that are designed to strengthen the immune system and enable it to outsmart your disease.

We are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer. Our platform employs allogeneic, autologous and genetically modified approaches to develop novel cell therapies, which are designed to effectively identify and eradicate tumor cells. We are one of the most advanced gamma-delta T cell companies and the first to bring genetically modified gamma-delta T cells into the clinic. Our lead product candidates are currently in Phase 1 clinical trials: INB-200, for the treatment of newly diagnosed glioblastoma, or GBM, and INB-100, for the treatment of patients with leukemia that are undergoing hematopoietic bone marrow transplantation. Our platform has yielded a broad portfolio of preclinical and discovery-stage programs, focused on addressing solid tumors.

Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems, and can intrinsically differentiate between healthy and diseased tissue. These cells serve as a functional bridge between innate and adaptive immunity to contribute to direct tumor killing as well as immune cell recruitment and activation to drive deeper immune responses. The pivotal role of gamma-delta T cells in immune function and activation, against diseases such as cancer, underscores their therapeutic potential across a wide range of solid and hematologic malignancies. We develop ex vivo expanded and activated gamma-delta T cell based upon our deep expertise in gamma-delta T cell biology, proprietary genetic engineering and cell-type specific manufacturing capabilities, collectively known as our DeltEx platform.

We are dedicated to leveraging our DeltEx platform to develop next generation cell therapies that we believe can dramatically improve outcomes for cancer patients. We have assembled a team of experts in the discovery and development of gamma-delta T cell based therapies. We are led by William Ho, our founder and Chief Executive Officer, who has over 20 years of combined experience in the management of biotechnology companies and healthcare finance and investing. Our scientific founder and Chief Scientific Officer, Dr. Lawrence Lamb, is a pioneer in the field of gamma-delta T cell biology and manufacturing, who published the foundational work that identified the potential antileukemic effect of these cells and their association with improved overall survival. Dr. Lamb’s expertise has directed the development of our DeltEx platform and he leads our Scientific Advisory Board, which includes a globally renowned group of clinicians, oncologists and immunologists.